Atopic Dermatitis Guidelines: What s New?
|
|
- Rosaline Bryant
- 6 years ago
- Views:
Transcription
1 Atopic Dermatitis Guidelines: What s New? Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego
2 Anacor/Pfizer Genentech Lilly Regeneron/Sanofi; Medimetriks Otsuka Galderma Laboratories Novan Valeant PharmaceuIcals DISCLOSURES Lawrence F. Eichenfield, MD Discussion is based on evidence-based recommendations and published or scientifically vetted, well designed studies
3
4
5 What s New in Guidelines
6 Food Allergy: DefiniIons " Food allergy food intolerance " Food allergy is defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food Boyce JA et al. J Allergy Clin Immunol Dec;126(6 Suppl):S1-58
7 Food Allergy Guidelines suggest that children less than 5 years of age with moderate to severe AD be considered for FA evaluaion for milk, egg, peanut, wheat and soy, if at least one of the following is met: -Persistent AD in spite of opimized management and topical therapy -History of an immediate reacion auer ingesion of Boyce a specific JA et al. J food Allergy Clin Immunol Dec;126(6 Suppl):S1-58
8 How common is food allergy in children with AD? Older figures: 30-50% Mild to moderate AD: ABOUT 15-16% Spergel JM et al. Pediatrics 2015(Dec)136:e1530-8
9 How common is food allergy? And is IgE tesing reliable? Study of infants with AD: 3-18 mths Pimecrolimus vs. Vehicle, TCS rescue trial) 36 mth trial; up to 33 mth open label phase sige: Baseline, End DB, end OL phase 15.9% had at least 1 food allergy Peanut 6.6%; Cow s milk 4.3%; Egg white 39% PosiJve tests had poor predicjve value! Spergel JM et al. Pediatrics 2015(Dec)136:e Silverberg JI, Simpson EL. Pediatr Aller Immunol. 2013;24(5):
10 Peanut ConsumpIon: Prevents Allergy! NegaIve skin-prick baseline Prevalence of peanut allergy at 60 mths: 13.7% in the avoidance group 1.9% in the consumpion group (P<0.001) IniIally posiive skin prick at baseline: 35.3% avoidance group 10.6% consumpion group Du Toit G, et al. N Engl J Med 2015;372:
11 New Food Allergy Guideline: NIAID 2017 Addendum to the 2010 guidelines for Diagnosis and Management of Food Allergy IdenIfies infants with severe AD (and/ Severe eczema: defined as persistent or frequently recurring or egg eczema allergy) with typical as group morphology at risk and for distribution, assessed as severe by a health care provider peanut and requiring allergy frequent need for prescriptionstrength topical corticosteroids, TCI, orother antiinflammatory agents despite appropriate use of emollients.
12 New NIAID Food Allergy Guidelines Recommends that infants with severe eczema, egg allergy or both have introducion of age-appropriate peanut-containing food as early as 4-6 months of age to reduce the risk of peanut allergy Direct referral to allergy or Serum IgE screen (if negaive, feed); if + referral to allergy
13 Food allergen panel testing or sige for other than peanut: not recommended
14 Mild to Moderate Eczema Introduce peanut-containing food as early as 4-6 months of age in accordance with family preferences and cultural pracices, to reduce the risk of peanut allergy. Peanut should not be the iniial solid food Peanut introduced at home without an in-office evaluaion. However, the EP recognizes that some caregivers and health care providers may desire an in-office evaluaion
15 Infants without eczema or food allergy Age-appropriate peanut-containing foods freely introduced in the diet, together with other solid foods, and in accordance with family preferences and cultural pracices.
16 Guidelines: What are we missing? Crisaborole: Place in therapy Have heard of requirement by insurance of an IGSA score! Dupilimab: Imminent approval? For which paients?
17
18 Topical PDE-4: How to use?
19 How about emerging biologics? Who are our target paients for new systemic therapies Moderate to severe
20 Dupilimab: inclusion criteria Chronic atopic dermaiis (according to American Academy of Dermatology Consensus Criteria) that has been present for >3 years before screening EASI score of >16 at screening and baseline IGA score of> 3 (on a scale of 0-4, in which 3 is moderate and 4 is severe) at screening and baseline >10% BSA screening and baseline Baseline pruritus numerical raing scale average for maximum itch intensity of >3, based (avg during the 7 days prior)
21 Dupilimab: inclusion criteria Documented recent history (within 6 months prior to screening) of inadequate response to treatment with topical medicaions, or for whom topical treatments are otherwise medically inadvisable (e.g., because of side effects or safety risks) Inadequate response: failure to achieve and maintain remission or a low disease acivity state (comparable to an IGA score of 0 [indicaing clear] to 2 [indicaing mild] despite treatment with a daily regimen of topical coricosteroids of medium to higher potency (with or without topical calcineurin inhibitors as appropriate), applied for >28 days or for the maximum duraion recommended OR SYSTEMIC THERAPY in PAST 6 MTHS
22 SEVERITY: Policy: Any statements? InternaIonal Eczema Council SystemaIc and holisic approach to assess severe signs/symptoms of AD and/or impact on quality of life Considering alternate or concomitant diagnoses, avoid trigger factors, opimize topical therapy, ensure paient/caregiver educaion, treat co-existent infecion, consider phototherapy
23 Diagnosis and Assessment: Diagnosis Caveats Allergic contact dermaiis: alternaive diagnosis and/or exacerbator NutriIonal, metabolic, and immunologic condiions in children and cutaneous T-cell lymphoma in adults Be aware of muliple infecions (bacterial or viral), failure to thrive Eichenfield LF et al, Part 1, JAAD, 2014;70:338-51
24 Diagnosis and Assessment: What are the Standards? Should query itch, sleep, impact on daily ac.vity, and disease persistence Be Aware and Discuss AssociaIons (as appropriate) ATOPIC: food allergies, asthma, rhiniis/rhinoconjunciviis Sleep disturbance, depression, and other neuropsychiatric condiions Eichenfield LF et al, Part 1, JAAD, 2014;70:338-51
25 Patch TesIng in Atopics Considered with persistent/recalcitrant disease and/or a history or physical examinaion findings consistent with allergic contact dermaiis Sidbury R et al. Part 4, JAAD 2014;71:
26 EducaIonal IntervenIons EducaIonal material: recommended adjunct Discussion of steroid strengths and safety EducaIonal and InstrucIonal materials Wrisen acion plans, Web-sites, Video training modules, Text/ reinforcers, Apps Sidbury R et al. Part 4, JAAD 2014;71:
27 Systemic Therapy: Assessing Need for Systemic Rx Signs scores: (not preferred); EG: IGSA (InvesIgator Global StaIc Assessment);EASI (not so easy!) BSA: 10% + (Psoriasis); not bad for AD, but not so good SCORAD (signs+symptoms): Not so pracical
28 Systemic Therapy: Assessing Need Recalcitrance: failure to respond to adequate topical therapy; requirement for prolonged use of high potency topical steroids; repeated flares
29 AD: The PoliIcs Excellent collaboraion amongst dermatologists, allergists Research work, guidelines, clinical collaboraions IniIaIves: CUBE-C (CoaliIon United for Beser Eczema Care) Co-chaired by Allergists! Developed through NaIonal Eczema AssociaIon to create a standardized curriculum on AD TherapeuIc PaIent EducaIon Movement: It s happening (April 8, 2017; San Diego) Access and Cost issues for new medicaions: Much work to do!
30 Summary: AD EvoluIon/RevoluIon Guidelines will need to be updated! Messaging: ESTABLISH THAT AD can and should be adequately controlled Parallels to asthma treat to no wheeze! Get ready for access work- Advocacy for and with our paients!
Lawrence F. Eichenfield, M.D.
What s New in Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence F.
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationPediatric Inflammatory Skin Disease Update. Inflammatory Skin Diseases. Factors influencing development of atopic dermatitis.
Pediatric Inflammatory Skin Disease Update Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVE At the conclusion of this activity, participants should be better able to: Answer common patient questions about the course of atopic dermatitis (AD) and effective strategies for treating
More informationWhat s New in Atopic Dermatitis?
What s New in Atopic Dermatitis? SMITA AWASTHI, MD ASSISTANT CLINICAL PROFESSOR, DEPT. OF DERMATOLOGY AND PEDIATRICS UNIVERSITY OF CALIFORNIA, DAVIS Disclosures No financial disclosures relevant to this
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationFood Allergy Update: To Feed or Not to Feed?
Food Allergy Update: To Feed or Not to Feed? Myngoc Nguyen, M.D. Allergy Department KP EBA Objectives: Prevalence of food allergy, clinical manifestation, diagnosis,component testing, oral challenges.
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationBeacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care
Beacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care Alan D. Irvine MD DSc Lecture overview What causes AD How to get optimise results in primary care Eczema and
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate
5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema Luz Fonacier, MD Professor of Clinical Medicine State University of New York at Stony Brook Head of Allergy & Training Program Director
More informationFood allergies and eczema
Department of Dermatology Food allergies and eczema Information for parents and carers Eczema, also known as atopic eczema or atopic dermatitis, is a skin condition that causes inflammation and irritation.
More information20/11/55. Food Allergy and Atopic Dermatitis. Outline of Talk - 1. Outline of talk - 2
Food Allergy and Atopic Dermatitis Pakit Vichyanond, MD Department of Pediatrics Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok, Thailand Outline of Talk - 1 Frequency of food sensitization
More information2/10/2017 THE NUTS AND BOLTS OF FOOD ALLERGY LEARNING OBJECTIVES DEFINITIONS
THE NUTS AND BOLTS OF FOOD ALLERGY Amanda Hess, MMS, PA-C San Tan Allergy & Asthma Arizona Allergy & Immunology Research Gilbert, Arizona LEARNING OBJECTIVES 1. Discuss the epidemiology, natural history
More informationEmerging Science and Management of Atopic Dermatitis
A CME/CE-CERTIFIED SUPPLEMENT TO Emerging Science and Management of Atopic Dermatitis Page 3 Introduction 4 The Disease Burden of Atopic Dermatitis 7 Food Allergy and Atopic Dermatitis: Fellow Travelers
More informationFood Allergy Testing and Guidelines
Food Allergy Testing and Guidelines Dr Gosia Skibinska Primary Care Allergy Training Day, 15 th October 2011 Food Allergy Testing and Guidelines Food allergy Testing Guidelines Cases Food Allergy NICE
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope November 7, 2016 Background: Atopic dermatitis (eczema) is a chronic/chronically-relapsing
More informationMarch 9, 2015 From: The Pediatric Dermatology Research Alliance (PeDRA)
Web: www.pedraresearch.org From: The Pediatric Dermatology Research Alliance (PeDRA) To: Jennifer Shepherd, Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Ave.,
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationExpert Analysis of Emerging Atopic Dermatitis Therapy Studies. A CE/CME Activity
Expert Analysis of Emerging Atopic Dermatitis Therapy Studies Overview A CE/CME Activity Lawrence F. Eichenfield, MD, and Jonathan I. Silverberg, MD, PhD, MPH, provide their perspectives on the clinical
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationLessons Learned from the International Eczema Council (IEC)
Lessons Learned from the International Eczema Council (IEC) Amy S. Paller, MD Northwestern University Feinberg School of Medicine American Academy of Dermatology meeting F046 February 17, 2017 No conflicts
More informationItchy babies: Current treatment guidelines for atopic dermatitis
Itchy babies: Current treatment guidelines for atopic dermatitis Rachel Laarman, MD Helen DeVos Children s Hospital Grand Rapids, MI Photo cred: www.dermatologytimes.modernmedicine.com I have no disclosures
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationAuthor s response to reviews
Author s response to reviews Title: The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study Authors:
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationFeed those babies some peanut products!!!
Disclosures Feed those babies some peanut products!!! No relevant disclosures Edward Brooks Case presentation 5 month old male with severe eczema starting at 3 months of age. He was breast fed exclusively
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationAilléirge Péidiatraiceach. Pediatric Allergy 3/9/2018. Disclosures & Conflicts Of Interest
Ailléirge Péidiatraiceach Michael Zacharisen, M.D. Allergy/Immunology Pediatric Allergy Michael Zacharisen, M.D. Allergy/Immunology Disclosures & Conflicts Of Interest Green Bay Packer fan I drive a Jeep
More informationGlenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
More information15 minute eczema consultation
THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationObjectives. Disclosures. Eosinophilic Esophagitis and Nutritional Consequences. Food Allergy In Schools
Eosinophilic Esophagitis and Nutritional Consequences Douglas T. Johnston, DO, FACAAI, FAAAAI Assistant Professor of Internal Medicine / Allergy & Immunology Edward Via College of Osteopathic Medicine
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLearning Objectives 10/26/2017. New Treatments in Atopic Dermatitis
New Treatments in Atopic Dermatitis Lynda C. Schneider, MD Professor of Pediatrics, Harvard Medical School Boston Children s Hospital lynda.schneider@childrens.harvard.edu Disclosures: Lynda Schneider,
More informationATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS. Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine
ATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine THE PLAN Is it atopic dermatitis? What is atopic dermatitis? Guidelines
More information2/25/17. Translating the Evidence: Allergy vs. Dermatology. How can they disagree?! Bias: It doesn t come out in the wash. wash. Precision Medicine
Translating the Evidence: Allergy vs. Dermatology Peter A. Lio, MD, FAAD Assistant Professor Clinical Dermatology & Pediatrics Northwestern University Feinberg School of Medicine How can they disagree?!
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Public Meeting May 25, 2017
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Public Meeting May 25, 2017 Welcome and Introduction Midwest Comparative Effectiveness Public Advisory Council (CEPAC) The Institute
More informationRecognition & Management of Anaphylaxis in the Community. S. Shahzad Mustafa, MD, FAAAAI
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures None Outline Define anaphylaxis Pathophysiology Common causes Recognition and Management Definition Acute,
More informationPaediatric Food Allergy. Introduction to the Causes and Management
Paediatric Food Allergy Introduction to the Causes and Management Allergic Reactions in Children Prevalence of atopic disorders in urbanized societies has increased significantly over the past several
More informationApproach to eczema. Hugo Van Bever Department of Pediatrics NUHS - Singapore
Approach to eczema Hugo Van Bever Department of Pediatrics NUHS - Singapore APAPARI workshop, Yangon, October 30, 2016 Eczema in children 1. Atopic dermatitis 2. Constitutional eczema 3. Contact dermatitis
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAllergy Testing in Childhood: Using Allergen-Specific IgE Tests
Guidance for the Clinician in Rendering Pediatric Care CLINICAL REPORT Allergy Testing in Childhood: Using Allergen-Specific IgE Tests Scott H. Sicherer, MD, Robert A. Wood, MD, and the SECTION ON ALLERGY
More informationAllergy and Breast Feeding CON (?) Hugo Van Bever Department of Pediatrics NUHS Singapore
Allergy and Breast Feeding CON (?) Hugo Van Bever Department of Pediatrics NUHS Singapore WAC, Cancun, December 2011 As a pediatrician are you crazy? Breast milk is the best! 1. Nutritional 2. Psychological
More informationIs it allergy? Debbie Shipley
Is it allergy? Debbie Shipley Topics Food Allergy and Eczema Hand Eczema and Patch Testing Urticaria Tackling Allergy Gell and Coombs classification Skin conditions with possible allergic component Allergy
More information7/25/2016. Use of Epinephrine in the Community. Knowledge Amongst Paramedics. Knowledge Amongst Paramedics survey of 3479 paramedics
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures Speaker s bureau Genentech, Teva Consultant Genentech, Teva Outline Knowledge gap Definition Pathophysiology
More informationDupilumab for treating adults with moderate to severe atopic dermatitis [ID1048]
Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can
More informationAtopic Dermatitis and Topical Antipsoriatics
Atopic Dermatitis and Topical Antipsoriatics Goal(s): Restrict dermatological drugs only for funded OHP diagnoses. Moderate/severe psoriasis and moderate/severe atopic dermatitis treatments are funded
More informationPositioning New Treatments for Atopic Dermatitis in Our Practice Parameter
40 th Annual Pulmonary and Allergy Update Positioning New Treatments for Atopic Dermatitis in Our Practice Parameter Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics
More informationAppendix 9B. Diagnosis and Management of Infants with Suspected Cow s Milk Protein Allergy.
Appendix 9B Diagnosis and Management of Infants with Suspected Cow s Milk Protein Allergy. A guide for healthcare professionals working in primary care. This document aims to provide health professionals
More informationUpdates in Food Allergy
Updates in Food Allergy Ebrahim Shakir MD Disclosures None 1 OUTLINE ADVERSE REACTIONS TO FOODS? Conflation of terms What is food allergy? ALLERGY Sensitization Gel/Coombs Type I IgE mediated Immediate
More informationEichenfield: Neonatal Dermatology
What You Need to Know about Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Disclosures
More informationAllergy 101. Lori Connors, MD, MEd, FRCPC Allergy and Clinical Immunology. Dalhousie University Mini Medical School Oct 19, 2017
Allergy 101 Lori Connors, MD, MEd, FRCPC Allergy and Clinical Immunology Dalhousie University Mini Medical School Oct 19, 2017 Objectives By the end of this talk participants will be able to: Define allergy
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationipad Increasing Nickel Exposure in Children
ipad Increasing Nickel Exposure in Children abstract We discuss allergic contact dermatitis to the ipad to highlight a potential source of nickel exposure in children. Pediatrics 2014;134:e580 e582 AUTHORS:
More informationDiscover the connection
Mike is about to have gastrointestinal symptoms, and his parents won t know why Milk Soy milk Wheat bread Egg FOOD ALLERGY Symptoms and food allergies Discover the connection ImmunoCAP Complete Allergens
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Evidence Report May 12, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff David M. Rind, MD, MSc Chief
More informationProfessor Rohan Ameratunga Clinical Immunologist and Allergist Auckland
Professor Rohan Ameratunga Clinical Immunologist and Allergist Auckland 16:30-17:25 WS #170: Eczema Management 17:35-18:30 WS #182: Eczema Management (Repeated) Managing ECZEMA A/Prof Rohan Ameratunga
More informationATOPIC DERMATITIS IN CHILDREN. Simple choice questions
ATOPIC DERMATITIS IN CHILDREN Simple choice questions 1. Which is the principal cause of atopic dermatitisdevelopment in little age children? A. Psychoemotional factors. B. Habitual antigens. C. Food allergy.
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationRELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN
RELEVANT DISCLOSURES MANAGING ECZEMA IN INFANTS AND CHILDREN Advisory board member - MEDA (Elidel), Speaking honoraria Bayer (Advantan) Advisory board, consultant, speaker: Pfizer, Abbvie, Janssen, Elli
More informationUNDERSTANDING ATOPIC DERMATITIS IN ITALY
UNDERSTANDING ATOPIC DERMATITIS IN Key points: Around 17% of people in Italy would have atopic dermatitis (AD) at some point in their life known as lifetime prevalence ; the disease is highly prevalent
More informationRand E. Dankner, M.D. Jacqueline L. Reiss, M. D.
Tips to Remember: Food allergy Up to 2 million, or 8%, of children, and 2% of adults in the United States are estimated to have food allergies. With a true food allergy, an individual's immune system will
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationClinical guideline Published: 12 December 2007 nice.org.uk/guidance/cg57
Atopic eczema in under 12s: diagnosis and management Clinical guideline Published: 12 December 2007 nice.org.uk/guidance/cg57 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationUNDERSTANDING ATOPIC DERMATITIS IN THE US
Key points: Resources for training general practitioners to treat atopic dermatitis (AD) remain sparse and inconsistent. A lack of comprehensive data makes it difficult to assess the prevalence of AD in
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 6 Last Review Date: March 18, 2016 Xolair Description Xolair (omalizumab)
More informationThe Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah
The Itch That Rashes Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah 1 Conflict of Interest No conflict of interest Will discuss off label use of medications 2 3 Most likely diagnosis?
More informationManaging and Minimizing Flare-ups in Atopic Dermatitis
Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology
More informationTopical Doxepin Prior Authorization with Quantity Limit Program Summary
Topical Doxepin Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-3 Agent(s) Indication(s) Dosage & Administration Doxepin 5% cream Prudoxin (doxepin) cream 5% KS_PS_Topical_Doxepin_PAQL_ProgSum_AR1018
More informationFood allergy in children. nice bulletin. NICE Bulletin Food Allergy in Chlidren.indd 1
nice bulletin Food allergy in children NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin Food Allergy in Chlidren.indd 1 23/01/2012 11:04
More informationPaediatric Dermatology. What s New? Stephanie Menzies
Paediatric Dermatology. What s New? Stephanie Menzies Atopic Dermatitis Emollients in the newborn Randomised controlled trial in US & UK 124 neonates high risk for AD Full body emollient at least daily
More informationFood-allergy-FINAL.mp3. Duration: 0:07:39 START AUDIO
BMJ LEARNING VIDEO TRANSCRIPT File: Duration: 0:07:39 Food-allergy-FINAL.mp3 START AUDIO Adam Fox: Food allergy is an inappropriate immune response to food. Our immune systems should ignore food completely,
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 7 Last Review Date: September 15, 2016 Xolair Description Xolair (omalizumab)
More informationWhat are the different types of allergy?
What are the different types of allergy? The main types of allergy seen in primary care are: Food allergy Inhalant allergy Stinging insect (venom) allergy Medication allergy Allergic contact dermatitis
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationADVANCED DIPLOMA IN PRINCIPLES OF NUTRITION
ADVANCED DIPLOMA IN PRINCIPLES OF NUTRITION BY LAUREN OWENS RD BSC (HONS) Human Nutrition and DIetetics Course Educators: Thomas Woods, William Eames BY LAUREN OWENS @ShawPhotoTom Special Diets Semester
More informationUniversity Medical Center Utrecht, Utrecht, Netherlands; 2 University of Lübeck, Lübeck, Germany; 3
Dupilumab With Concomitant Topical Corticosteroids in Adult Patients With Atopic Dermatitis who are not Adequately Controlled With or are Intolerant to Cyclosporine A, or When This Treatment is Medically
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationAGING IN PLACE. Panel 3 - Health transi,on trajectories: Data to ac,on Jeff Kaye, Maureen SchmiDer- Edgecomb, Dan Siewiorek
AGING IN PLACE National Institutes of Health September 9-10 th, 2014 Panel 3 - Health transi,on trajectories: Data to ac,on Jeff Kaye, Maureen SchmiDer- Edgecomb, Dan Siewiorek OUTLINE 1. J. Kaye: Frameworks
More informationFood Allergy. Wesley Burks, M.D. Curnen Distinguished Professor and Chair Department of Pediatrics University of North Carolina
Food Allergy Wesley Burks, M.D. Curnen Distinguished Professor and Chair Department of Pediatrics University of North Carolina Faculty disclosure FINANCIAL INTERESTS I have disclosed below information
More informationDiagnostic Usefulness of the Serum-Specific IgE, the Skin Prick Test and the Atopy Patch Test Compared with That of the Oral Food Challenge Test
Ann Dermatol Vol. 22, No. 4, 2010 DOI: 10.5021/ad.2010.22.4.404 ORIGINAL ARTICLE Diagnostic Usefulness of the Serum-Specific IgE, the Skin Prick Test and the Atopy Patch Test Compared with That of the
More informationFood Allergy , The Patient Education Institute, Inc. imf10101 Last reviewed: 10/15/2017 1
Food Allergy Introduction A food allergy is an abnormal response to a food. It is triggered by your body's immune system. An allergic reaction to a food can sometimes cause severe illness or death. Tree
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationTest Name Results Units Bio. Ref. Interval ALLERGY, INDIVIDUAL MARKER, BANANA, SERUM (FEIA) 0.42 kua/l
LL - LL-ROHINI (NATIONAL REFERENCE 135091547 Age 28 Years Gender Female 1/9/2017 120000AM 1/9/2017 103610AM 1/9/2017 14658M Ref By Final ALLERGY, INDIVIDUAL MARKER, BANANA, SERUM 0.42 kua/l QUANTITATIVE
More informationThe natural history of atopic dermatitis and its association with Atopic March
Asian Pacific Journal of Allergy and Immunology ORIGINAL ARTICLE The natural history of atopic dermatitis and its association with Atopic March Sinjira Somanunt, 1 Sasawan Chinratanapisit, 2 Punchama Pacharn,
More informationFood Allergy I. William Reisacher, MD FACS FAAOA Department of Otorhinolaryngology Weill Cornell Medical College
Food Allergy I William Reisacher, MD FACS FAAOA Department of Otorhinolaryngology Weill Cornell Medical College History of Food Allergy Old Testament - Hebrews place dietary restrictions in order to prevent
More informationFaculty Disclosures Research Support Consultant
Faculty Disclosures Research Support Shire clinical area: eosinophilic esophagitis Regeneron clinical area: eosinophilic esophagitis Allakos clinical area: eosinophilic gastritis Consultant Shire clinical
More informationECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE
ECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE 1 OVERVIEW OF SURVEY RESULTS INTRODUCTION PATIENT INSIGHTS BY THE NUMBERS: Adult Atopic Dermatitis (AD) In the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Topical Doxepin Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationImmunotherapy for Food Allergy: Is it Ready for Primetime?
Immunotherapy for Food Allergy: Is it Ready for Primetime? Bruce J. Lanser, MD Assistant Professor of Pediatrics Director, National Jewish Health Pediatric Food Allergy Center Associate Director, Pediatric
More informationThe importance of early complementary feeding in the development of oral tolerance: Concerns and controversies
The importance of early complementary feeding in the development of oral tolerance: Concerns and controversies Prescott SL, Smith P, Tang M, Palmer DJ, Sinn J, Huntley SJ, Cormack B. Heine RG. Gibson RA,
More information